The Filtrate:

Joel Topf

Swapnil Hiremath

Sophia Ambruso

AC Gomez

Josh Waitzman

Jennie Lin

Nayan Arora

The Curbsiders

Matt F. Watto (@DoctorWatto)

Paul Nelson Williams, America’s primary care physician (@PaulNWilliamz)

With Special Guest:

JD Foster (@KidneyVet)

Sayed Tabatabai (@TheRealDoctorT) Nephrologist in Austin and the author of These Vital Signs

Michelle Rheault (@rheault_m) Chief of Pediatric Nephrology at the University of Minnesota and lead author of the DUPLEX Trial

Editor:

Joel Topf

Show Notes:

Lily toxicity in the cat (PubMed)

Surgeons perform kidney transplants in cats amid rising demand for advanced pet care (ABC News)

Treatment of ibuprofen toxicity with serial charcoal hemoperfusion and hemodialysis in a dog (PubMed)

Nephrology in Veterinary Medicine (Kidney 360)

Star Wars Society of San Antonio (FaceBook)

These Vital Signs (Amazon)

Dr Tabatabai read a short story called The Handholder, here is the original tweet thread for that story (ThreadReader)

The pearl not the patient (PubMed)

Late Braking and High Impact Clinical Trial press release

MENTOR, Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy, was in 2019 not 2017 (NEJM)

KALM-1, A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus, was in 2019 not 2017 (NEJM)

Sophie’s number one pick: Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial (Lancet)

Patients in the sparsentan group had a slower rate of eGFR decline than those in the irbesartan group. eGFR chronic 2-year slope (weeks 6–110) was −2·7 mL/min per 1·73 m2 per year versus −3·8 mL/min per 1·73 m2 per year (difference 1·1 mL/min per 1·73 m2per year, 95% CI 0·1 to 2·1; p=0·037); total 2-year slope (day 1–week 110) was −2·9 mL/min per 1·73 m2 per year versus −3·9 mL/min per 1·73 m2 per year (difference 1·0 mL/min per 1·73 m2 per year, 95% CI −0·03 to 1·94; p=0·058).

Clinical Trial Considerations in Developing Treatments for Early Stages of Common, Chronic Kidney Diseases: A Scientific Workshop Cosponsored by the National Kidney Foundation and the US Food and Drug Administration (AJKD)

AC Gomez’s Pick: MDR-101-MLK Update: Operational Immune Tolerance Achieved in Living Related HLA-Matched Kidney Transplant Recipients (ASN-Online.org)

Josh’s Pick: A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy (NEJM)

Nayan’s Pick: The EnAKT LKD Cluster Randomized Clinical Trial (JAMA Internal Medicine)

The Freely Filtered simultaneous release (NephJC)

Freely Filtered is now a verb.

Swap’s Pick: Strategies for the Management of Atrial Fibrillation in PatiEnts Receiving Dialysis (SAFE-D) (ASN-Online.org)

Joel’s Pick: AYAME Study: Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Bardoxolone Methyl in Diabetic Kidney Disease (DKD) Patients (ASN-Online.org)

Reata is a no-show to the 2012 ASN Kidney Week (PBFluids)

Michelle’s Pick: Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis. The DUPLEX Study (NEJM)

DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS (PubMed)